Validation of ROS1 by immunohistochemistry against fluorescent in situ hybridisation on cytology and small biopsy samples in a large teaching hospital.
Nadira NarineAndrew WallaceJonathan DoreSimon O'Leary-JacksonHaider Al NajjarSimon BaileyKashif KhanBenjamin TengMuhammad QasimDavid SheltonMiles HolbrookSalma AbbasiMatthew CarterLuciane IrionSamer Al-HabbaColin LindsayFiona BlackhallDurgesh RanaPublished in: Cytopathology : official journal of the British Society for Clinical Cytology (2021)
IHC to assess for the protein product of ROS1 gene rearrangement on cytology cell blocks and small biopsy samples in a routine setting is a promising screening method to assess eligibility for TKI treatment with positive and indeterminate cases confirmed by FISH or NGS as it has good negative predictive value, faster turnaround time and is cost effective, with proven technical and clinical validation.
Keyphrases
- fine needle aspiration
- ultrasound guided
- cell death
- dna damage
- reactive oxygen species
- single cell
- tyrosine kinase
- quantum dots
- clinical practice
- advanced non small cell lung cancer
- copy number
- living cells
- genome wide
- oxidative stress
- binding protein
- stem cells
- dna methylation
- protein protein
- transcription factor
- genome wide identification
- chronic myeloid leukemia